Introduction

Magnetic resonance imaging (MRI) is one of the most important tools for clinical imaging. Apart from its unlimited tissue penetration, MRI offers the advantages of being non-invasive and producing zero ionizing radiation. Because of being able to distinguish tumours from healthy tissue, it is considered essential for the diagnosis and prognosis of cancer as well as for surveying the efficacy of the pharmaco-therapy. Additionally, it is used for the preparation and guidance of surgical procedures (e.g., brain tumour resections) and for basic biomedical research.

An MRI of the human body is based on signals produced by water protons under a strong magnetic field. Since most of the human body is made up of water molecules, MRI can identify a given organ or tissue structure by detecting water proton density, proton velocity, and the longitudinal (T1) and transverse (T2) relaxation times. When the intrinsic contrast between diseased and healthy tissues is too low for an accurate diagnosis, contrast imaging agents are used to enhance the visibility of these differences.

Abstract

Gadolinium-containing carbon nanomaterials are a new class of contrast agent for magnetic resonance imaging. They are characterized by a superior proton relaxivity to any current commercial gadolinium contrast agent and offer the possibility to design multifunctional contrast agents. Intense efforts have been made to develop these nanomaterials because of their potential for better results than the available gadolinium contrast agents. The aim of the present work is to provide a review of the advances in research on gadolinium-containing carbon nanomaterials and their advantages over conventional gadolinium contrast agents. Due to their enhanced proton relaxivity, they can provide a reliable imaging contrast for cells, tissues or organs with much smaller doses than currently used in clinical practice, thus leading to reduced toxicity (as shown by cytotoxicity and biodistribution studies). Their active targeting capability allows for improved MRI of molecular or cellular targets, overcoming the limited labelling capability of available contrast agents (restricted to physiological irregularities during pathological conditions). Their potential of multifunctionality encompasses multimodal imaging and the combination of imaging and therapy.

Keywords

biodistribution, carbon nanomaterials, cell labelling, gadolinium contrast agent, magnetic resonance imaging, multifunctional contrast agent, toxicity
agents are intravenously administered. These chemical entities improve the visualization of tissues or organs by increasing the relative difference between the signal intensity. They improve MRI contrast by shortening the longitudinal (T1) and/or transverse (T2) relaxation times of water protons.

MRI contrast agents are classified as T1 or T2 according to the type of relaxation time that is improved. T1 predominantly reduces the longitudinal relaxation time of water protons, thus enhancing a positive (bright) contrast in imaging. Contrarily, T2 primarily diminishes the transverse relaxation time, improving the negative (dark) contrast. Regarding the T1-type, the main medical imaging agents for the visualization of tissues and organs contain gadolinium(III) [Gd(III)]. This metal ion couples a large magnetic moment with a long electron spin relaxation time. Although Gd(III) complexes have been administered to more than 100 million patients and demonstrated an extraordinarily positive safety record, it is necessary to develop new contrast agents that improve diagnosis accuracy.

Gadolinium-containing carbon nanomaterials, a new class of T1 contrast agents, rank among the most potent in terms of proton relaxivity ($r_1$). They induce 10- to 90-fold greater relaxivity than the available gadolinium-based agents. For example, the relaxivity induced by Gd(DTPA) or Gd(DOTA) is at about 4 mM$^{-1}$ s$^{-1}$ while for gadofullerenes is around $r_1 = 47.0 \pm 1.0$ mM$^{-1}$ s$^{-1}$. The new gadolinium contrast consists of carbon nanomaterials with gadolinium ions confined in their inner cavities or attached by ligands to functional groups on their external surface, tips or edges. The Figure 1 shows the principal four types of contrast agents: gadofullerenes, gadonanotubes, gadonanodiamonds and gadographene.

Compared to commercial products, the new contrast agents show several advantages. Recent reviews have discussed the advances of gadolinium-containing carbon nanomaterials in relation to the methods of synthesis as well as their chemical and physical properties. Each review has focused on a certain type of nanomaterial, such as gadonanotubes or gadofullerenes. The present review consists of an overview of gadolinium-containing carbon nanomaterials, comparing them with conventional gadolinium contrast agents and considering their advantages, disadvantages, cytotoxicity and biodistribution.

2 | POTENTIAL ADVANTAGES

There are several important advantages afforded by gadolinium-containing carbon nanomaterials compared to commercial contrast agents (Figure 2). Firstly, their greater proton relaxivity allows for the attainment of reliable images with a lower dose. Hence, less Gd(III)
ions are needed (<10-fold less than the current clinical dose) to produce the same brightness as available contrast agents.\textsuperscript{23} Secondly, specific cells, tissues and molecules can be targeted. Contrast selectivity is achieved by the modification of carbon nanomaterials with biopolymers such as DNA, RNA, peptides and proteins.\textsuperscript{24-28} Thirdly, carbon nanomaterials are able to translocate across membranes and label cells. Their excellent cell penetration likely results from their size, aspect ratio and amphiphilic surface character.\textsuperscript{29-31} Fourthly, these carbon nanomaterials have multifunctional potential. Their optical properties permit the design of contrast agents capable of multimodal imaging.\textsuperscript{32} Their large surface area and chemically tailorable surface enable molecules to be efficiently loaded by covalent and non-covalent functionalization for a combination of imaging and therapy.

2.1 Reduced amount of the contrast agent required to obtain reliable images

Gadolinium-containing carbon nanomaterials have been consistently found to induce high proton relaxivity.\textsuperscript{33} In 1997, Zhang et al\textsuperscript{35} reported that gadofullerenes produce a nearly 10-fold greater relaxivity of gadonanotubes ($r_1 = 170$ mM$^{-1}$ s$^{-1}$) compared to gadofullerenes. Soon after, the same group published the first T1-weighted MRI phantoms of gadonanotubes\textsuperscript{36} (Figure 3B). In 2010, Manus et al\textsuperscript{37} found a nearly 10-fold greater relaxivity of gadonanodiamonds ($r_1 = 58.82 \pm 1.18$ mM$^{-1}$ s$^{-1}$) compared to the current contrast agents. They reported the first T1-weighted MRI phantoms with gadonanodiamonds (Figure 3C). In 2012, Shen et al\textsuperscript{38} showed the high relaxivity produced by gadogaphene, demonstrated by the first T1-weighted MRI phantoms with this contrast agent (Figure 3D).

Although the working mechanism for the superior relaxivity of gadolinium-containing carbon nanomaterials is still not well understood, it is often described by the Solomon, Bloembergen and Morgan (SBM) theory. This theory, initially developed to explain the proton relaxivity of gadolinium chelated contrasts, provides insights into gadolinium-containing carbon nanomaterials. Several parameters of the SBM theory can help to account for the observed high relaxivity of the new carbon contrast. These include the number of water molecules co-ordinated to the paramagnetic centre ($q$), the rotational correlation time (TR) and the mean residence life-time of the co-ordinate waters (TM).

The number of water molecules co-ordinated is considered one of the most important. Gd(III) is a paramagnetic element with a fluctuating magnetic field that interacts with nearby water molecules and thus shortens their T1 and T2 relaxation times and improves the bright contrast in MR imaging.\textsuperscript{39} The Gd(III) complex is hydrated by three different types of water molecules that may be affected by the magnetic field (Figure 4). According to the SBM theory, proton relaxivity enhancement is more pronounced for water molecules directly co-ordinated to the paramagnetic centre ($q=1$) and a relaxivity of approximately of four. For example, Gd(DTPA) displays an $r_1$ value of $4.30$ mM$^{-1}$ s$^{-1}$. Gadonanotubes, on the other hand, reportedly contain a large number of co-ordinated water molecules per Gd(III) ($q = 9$), as suggested by X-ray absorption spectroscopic analysis,\textsuperscript{40} which may explain their elevated relaxivity compared to commercial gadolinium chelated contrast agents. The $q$ value has also been employed to account for the superior performance of gadofullerenes vs commercial agents. The paramagnetic properties of Gd(III) are considered to be conserved and transferred to the fullerene cage in gadofullerenes, where the Gd(III) ion is encapsulated.\textsuperscript{41,42} Consequently, there is an enhanced surface area accessible to water molecules, allowing a larger number of them to have direct contact with the paramagnetic centre and undergo the transmission of relaxivity. For gadofullerenes and gadonanotubes, it was reported a second-sphere-like mechanism also plays a key role.\textsuperscript{43} This second-sphere-like is originated by a large number of water molecules bounded to the...
functional groups present in the carbon nanostructure surface, which increases the probability of waters protons to be exchanged. The SBM theory also considers the rotational correlation time (TR), which refers to the tumbling rate of the contrast agents. Small gadolinium contrasts agents tumble too fast, near the tenths of picoseconds, and in order to decrease their tumbling rate they are usually coupled to polymers of high molecular weight. Magnetic relaxation dispersion profiles (NMRD) and dynamic light scattering (DLS) analysis have shown the size of the gadofullerenes and their aggregation state are linked with their rotational correlation time. Laus et al. reported the disaggregation of Gd@C_{60}(OH)_{x} and Gd@C_{60}[C(COOH)_{2}]_{10} by salt addition leads to more rapidly tumbling rates and lower relaxivities. Tóth et al. found the TR of Gd@C_{60}[C(COOH)_{2}]_{10} decreases when it is disaggregated, from TR = 2.6 ns to TR = 1.2 ns. In the case of gadonanotubes, NMRD studies have shown, gadonanotubes have relaxation profiles characteristic of gadolinium ions co-ordinated to a slowly tumbling environment.

On the other hand, it was found the carbon structure also plays a key role for water proton relaxation. Moghaddam et al. found the carbon-based radical centres that are supported by the polynuclear aromatic structure contribute at low magnetic fields (<1 MHz).

Until now, several parameters have described the relaxivity of gadolinium-containing carbon materials, however, there is a necessity to develop new theoretical approaches for a most robust description [for a more comprehensive review, see15,40,49,50].

One of the most important implications of the heightened relaxivity of gadolinium-containing carbon nanomaterials compared to conventional contrast agents is the reduction of the dose of Gd(III) required to evaluate areas of clinical interest (Figure 3). For example, Mikawa et al. found the MRI signal to be stronger for polyhydroxylated gadofullerenes than Gd-DTPA when both had an equivalent concentration of Gd(III). Li et al. pointed out that the concentration of Gd-DTPA should be 50-fold higher than amino functionalized gadofullerenes in order to achieve the same contrast.

Fatouros et al. obtained equivalent contrast intensity with pegylated-hydroxylated gadofullerenes and gadodiamide (Omniscan), even though the latter had to be administered at a 30-fold higher concentration. Sitharaman et al. applied gadonanotubes and Magnevist at the same concentration and observed an ~100-fold higher signal intensity for the former.

2.2 Easy targeting of the contrast agent towards specific cells, tissues or molecules

Nowadays, research on non-invasive imaging focuses on the development of tools for detecting biomarkers, which are unique
biochemical signatures that differentiate and characterize tissues in a diseased state at the cellular or molecular level. MRI provides high-resolution images to evaluate anatomical structures but has limited sensitivity to visualize biomarkers. MRI images of diseased tissues are generally formed by the accumulation of the contrast agent at sites with histological irregularities. For example, due to the abundant vascularization existing in brain tumours and the consequent presence of pores in the blood-brain barrier, contrast agents can diffuse freely and accumulate in the tumour, thereby facilitating MR imaging. Contrarily, contrast agents are not able to cross the blood-brain barrier in healthy tissue.

Another disadvantage of MRI is the inability of most contrast agents to cross intact membranes, restricting them to the extracellular space and thus making it impossible for them to target intracellular biomarkers. To overcome these disadvantages, scientist has focused on the development of new contrast agents to improve the MRI potential for the detection of biomarkers at the cellular or molecular level. In particular, the efforts have been focused on ‘active targeting’ concept, which involve the binding of certain ligands to receptors overexpressed on the surface of cancer cells, allowing for the uptake and retention of the contrast agent and as a consequence the imaging of the molecular targets.

The active targeting concept inspired the development of gadolinium-based carbon nanomaterials, in which single amino acids, small peptides, cyclic peptides, proteins and organic molecules are integrated as ligands to target specific cells. For instance, Shu et al worked with antibodies able to recognize the green fluorescent protein. These antibodies were bound to carboxylic functional groups of gadofullerenes and the authors suggested that this strategy can be extended to other biomolecules or endohedral fullerences.

Fillmore et al reported the covalent binding of the cytokine interleukin-13 (IL-13) peptide to the carboxylic groups on gadofullerenes. They selected IL-13 because of its high affinity for the IL-13Rα2 receptor, which is overexpressed on human glioma cells. When comparing gadofullerenes with and without the IL-13 functionalization, the former displayed a 64-fold greater in vitro uptake. The authors also actively targeted a tumour in mouse brain (implanted with the inoculation of U87 cells) with functionalized gadofullerenes and could achieve MR imaging. Years later, they actively targeted a brain tumour with gadofullerenes bearing amino groups (rather than carboxylic groups) for the covalent binding of IL-13. This conjugate system produced images with a sharp definition of the tumour, unlike the low-quality tumour outline obtained with Magnevist (the control) (Figure 5). Since active targeting improved the capacity of MRI to detect tumours, the concentration employed was up to 50% lower than that of traditional control contrast agents.

Gadofullerenes have been modified with folic acid as well, a ligand with high affinity for its cell membrane receptor, which is overexpressed on the surface of many types of cancer cells (lung, ovary, breast, brain, kidney, colon and endometrium). For instance, Zheng et al compared unmodified gadofullerenes to those functionalized with folic acid (Figure 6), finding a preferential uptake of the latter by cancer cells under in vitro conditions.

More recently, Han et al explored the active targeting of extracellular matrix proteins. This strategy emerged as alternative due to the difficulties to target cancer cells and is based in findings that have shown certain proteins are abundantly expressed in regions surrounding tumours and at basal levels in healthy tissues. Han et al functionalized gadofullerenes with the small peptide ZD2 (Cys-Thr-Val-Arg-Thr-Ser-Ala-Asp), which has high affinity towards the extra domain-B fibronectin (EDB-FN), a protein abundantly expressed in the extracellular matrix of many types of aggressive human cancers (Figure 7). Hence, these tumours can be targeted in vitro and in vivo, facilitating their detection with MRI.

In summary, specific functionalization of gadofullerenes with high-affinity ligands by biomarkers has enabled the active targeting of tumours at a cellular and molecular level, leading to increased MRI capability.

### 2.3 Potential for the design of multifunctional nanoprobes

A multifunctional probe is a contrast agent that serves multiple imaging modes or is able to facilitate imaging and therapy at the same time. Although current small gadolinium-based contrast agents have the possibility of multifunctionality, their chemical function is complex and multiple steps are required for their synthesis. In contrast, carbon nanomaterials require minimal steps to increase their multifunctionality. For instance, it is possible, in the absence of a chemical reaction, to non-covalently functionalize carbon nanomaterials with...
Taking advantage of this several multifunctional contrast agents had developed. For instance, Cisneros et al. developed gadonanotubes in the absence of a chemical reaction, to be used for imaging with MRI and positron emission tomography (PET). They loaded ultrashort single-walled carbon nanotubes with both Gd(III) and Cu(II) ions to form the conjugate Cu(II)@gadonanotube, which has the dual capability of imaging with PET and MRI scans. There are apparatuses capable of performing both scans. The same research group also recorded dynamic PET/CT images on a healthy mouse with the same contrast agent, reporting its stability and quick clearance from circulation. Thus, they developed contrast agents that combine the excellent spatial and contrast resolution of MRI with the high sensitivity of PET. Also, Luo et al. carried out PET/MRI dual imaging by functionalizing gadofullerenes with 124I to afford an 124I-f-Gd3N@C80 nanoprobe. The in vivo imaging visualization with both MRI and microPET demonstrated the dual properties of the 124I-f-Gd3N@C80 agent (Figure 8).

The multifunctionality of gadonanotubes also includes the combination of imaging and therapy. Matson et al. developed the
conjugate $^{225}$Ac(III)@gadonanotubes by loading short single-walled carbon nanotubes with both $^{225}$Ac(III) and Gd(III) ions. They chose the $^{225}$Ac(III) ion because of being a potent α-particle ($^4$He$^2$) generator with therapeutic value. Additionally, Peci et al. functionalized the sidewalls of iron-filled multi-walled carbon nanotubes with gadolinium ions, suggesting that the complexes may be good candidates for MR imaging and magnetic hyperthermia. Recently, Wang et al. fabricated a polydopamine-encapsulated gadolinium-loaded multi-walled carbon nanotube (MWCNT-Gd@DPA) for MR imaging and photothermal therapy (PPT) (Figure 9). They took advantage of the optical properties of carbon nanotubes, which have a high infrared wave range (NIR) conversion efficiency and thus can produce a great increase in local temperature that is capable of killing cancer cells. According to the in vivo and in vitro results, the conjugate was able to map the lymph nodes in mice by inducing metastasis and served a therapeutic purpose after being irradiated with a NIR laser.

More recently, Zhang et al. synthesized yet another complex for imaging and therapy. They decorated multi-walled carbon nanotubes (MWCNTs) with magneto-fluorescent carbon quantum dots (GdN@CQDs), doxorubicin and the EGFR antibody (GP-GdN@CQDs-MWCNTs/DOX-EGFR). Whereas carbon nanotubes can absorb in the near-infrared wave range (NIR), the magnetic and fluorescent properties of the magneto-fluorescent carbon quantum dots (GdN@CQDs) are instrumental for achieving MR and fluorescence dual-mode imaging. Doxorubicin was selected because it is a common chemotherapy agent administered to treat several types of cancers, while the EGFR antibody has both therapeutic properties and active targeting capabilities against cancer cells. The nanocomposite was used for imaging and chemo-photothermal therapy in nude mice bearing tumours, resulting in the elimination of 100% of the tumours.

All these works have shown gadolinium-based contrast agents have the possibility of multifunctionality overcoming the limitations of current contrast agents for multifunctional imaging and the combination of imaging and therapy.

### 2.4 | Cell labelling capability

MRI is an ideal tool for in vivo imaging and tracking of engrafted cells for regenerative medicine because it can image deep inside tissue, gives accurate anatomical and physiological information and offer the possibility of monitoring transplanted cells over long periods of time. However, due to their intrinsic low relaxivity and short blood circulation time, conventional gadolinium contrast agents are not suitable for cell labelling. In contrast, a great staining efficiency has been observed with gadolinium-containing carbon nanomaterials. Anderson et al. examined cell staining with polyhydroxyl Gd@C$_{82}$ as a T1 contrast agent and found that complexing gadofullerenes with protamine sulphate (a transfection agent) increased cell labelling, allowing for visualization of the cells by MR imaging in vitro and in vivo. Rammohan et al. employed gadonanodiamonds for the
labelling of cancer cells (MDA-MB-231m-Cherry human triple-negative breast cancer cell line). Based in gadolinium quantification they found gadonanodiamonds confers 300-fold improvement in cellular delivery of Gd(III) compared to Gd(III)−DOTA and conventional contrast agents (Gd−C₅−COOH). Also, the MR images of a mouse bearing a gadonanodiamonds-labelled xenograft confirmed the viability of gadonanodiamonds for MRI and cell tracking.

Recently, Zhang et al. developed a gadographene for staining human mesenchymal stem cells. The contrast was synthesized by PEGylation of ultrasmall graphene oxide, followed by conjugation with a chelating agent (DOTA) and then Gd(III) to form GO-DOTA-Gd complexes. The authors demonstrated the efficient labelling of human mesenchymal stem cells by GO-DOTA-Gd (Figure 10A), without any apparent adverse effects on proliferation and differentiation of the cells. The cells could be visualized by MRI after implantation into nude mice in vivo (Figure 10B).

The excellent cell penetration of cell membranes by gadolinium-loaded carbon nanomaterials and their retention inside cells may explain their cell staining capability. Some studies have evaluated the internalization and subcellular localization of gadolinium-containing carbon nanomaterials. For instance, Sitharaman et al. tested the cellular uptake and internalization of Gd@C₆₀(COOH)₂₀ in NIH 3T3 mouse fibroblast cells and bone marrow stromal cells (human mesenchymal stem cells). In both cases, they observed a saturation uptake of 0.5 mmol/L of gadolinium. Given that they did not detect any release of gadolinium from the cells within a 48-hour period, the internalization seems to be an irreversible process.

The cell internalization of gadonanotubes has also been described. For instance, according to Hassan et al., the internalization is less efficient for gadonanotubes dispersed with BSA than those functionalized with serine. In contrast, when working with the HELA and J774A.1 macrophage cell line, Holt et al. found that gadonanotubes dispersed with BSA were more internalized than those dispersed with the PF108 surfactant. Regarding the subcellular internalization, Avti et al. and Marangon et al. observed that gadonanotubes tended to be compartmentalized within endosomes in the cytoplasm of NIH/3T3 cells and RAW 264.7 mouse macrophages, suggesting an active process of cellular internalization. Nevertheless, Hassan et al., Tran et al. and Gizzatov et al. reported the formation of gadonanotube aggregates in the cytoplasm, but without encapsulation in vesicles (endosomes). Recently, Holt et al. used resonant Raman imaging to determine the subcellular distribution of gadonanodiamonds for multimodal imaging detection of brain tumours. (A, D) T1-weighted images with gadodiamide contrast. (B, E) T1-weighted images in which the bright contrast at the infusion site results from ¹²⁵I-f-Gd₃N@C₈₀. (C, F) T2-weighted images with dark contrast due to ¹¹⁸I-f-Gd₃N@C₈₀. (G) Coronal, (H) axial and (I) sagittal microPET images following ¹⁸F-FDG injection and the additive image signal that allows for localization of ¹²⁵I-f-Gd₃N@C₈₀ within the right hemisphere of the rat brain (arrows indicate infusion sites). (J-L) MicroPET images display the signal from ¹²⁵I-f-Gd₃N@C₈₀. Reprinted with permission from, copyright 2012 MDPI (http://creativecommons.org/licenses/by/4.0/)
rodríguez-galván et al.

**3787**

**FIGURE 9** Gadonanotubes for imaging and therapy. (A) Scheme of the synthetic strategy and the T1-MRI and colour mapping guided PTT of metastatic LNts by MWCNT-Gd@PDA-PEG. (B) IR thermal images of primary tumour and RLNs LNts with NIR illumination by an 808 nm laser. Reprinted with permission from, copyright 2017 Elsevier

Gadonanotubes, finding them predominantly in a perinuclear location of the cytoplasm (Figure 11) and that dispersal agents affected the degree of agglomeration. For instance, gadonanotubes dispersed with the PF108 surfactant accumulated randomly at high concentrations in distinct regions, while, gadonanotubes dispersed with BSA were more uniformly distributed throughout the cytoplasm.

**3 | IN VITRO AND ANIMAL MODEL SAFETY ASSESSMENTS**

The advantages of gadolinium-containing carbon nanomaterials over conventional contrast agents should certainly have an impact on several areas of medicine, especially imaging and therapy for cancer patients. However, it is necessary to assure the safety of nanoparticles (NPs) interacting with the organism at the cellular and systemic level. Hence, the cytotoxicity and biodistribution of gadolinium-containing carbon nanomaterials are presently explored to provide insights into their effects on biological systems.

### 3.1 | Cytotoxicity

One of the main concerns with the medical applications of carbon nanomaterials containing gadolinium ions is their cytotoxicity, because of the well-documented cell toxicity of carbon nanomaterials and the toxicity of Gd(III) ions. Several studies in cell cultures have shed light on cytotoxicity, cell viability and cell proliferation. Chen et al\(^7\) tested the cytotoxicity and cell viability of hydroxylated gadofullerenes ([Gd@C\(_{82}\)(OH)\(_{22}\)]\(_n\)) on human hepatoma cells (HepG2) and rat hepatoma cells (RH 35), finding no toxic effects at concentrations of \(2 \times 10^{-8}\) to \(1 \times 10^{-5}\) mol/L of Gd(III). They attributed the low levels of toxicity to the hydroxyl groups, which favour the dispersion of these fullerenes. Anderson et al\(^{30}\) also
analysed the cytotoxicity and cell viability of the hydroxylated gadofullerenes \( \text{Gd} @ \text{C}_{82}(\text{OH})_{40} \) in HeLa cells, human macrophages and human mesenchymal stem cells, reporting no difference with the control groups. Liu et al applied \( \text{Gd} @ \text{C}_{82}(\text{OH})_{22} \) to LLC cells, B cells, T cells and macrophages, finding no significant effects in relation to cytotoxicity or cell viability with doses of Gd(III) from 0.1 \( \mu \text{mol/L} \) to 100 \( \mu \text{mol/L} \). Sitharaman et al examined the cytotoxicity of \( \text{Gd} @ \text{C}_{60}[\text{C(COOH)}_{2}]_{10} \) in NIH 3T3 mouse fibroblast and bone marrow stromal cells (human mesenchymal stem cells). At a concentration of 500 \( \mu \text{mol/L} \) of Gd(III), the cells were unaffected during a 24 hours period.

Regarding the cytotoxicity of gadonanotubes, Tang et al demonstrated no significant effect on murine macrophage cells (J774A.1) at concentrations \( \leq 27.75 \mu \text{mol/L} \) of Gd(III), but cytotoxicity was indeed present at higher doses \( >27.75 \mu \text{mol/L} \) of Gd(III). Holt et al observed no cytotoxicity on HeLa cells and murine macrophage-like cells (J774A.1) exposed to carbon gadonanotubes at concentrations \( \leq 27 \mu \text{g/mL} \) of carbon nanotubes. Also, Servant et al observe no significant decrease in cell viability of HUVEC cells after 4 and 24 hours of exposure to long oxidized carbon gadonanotubes at concentrations \( \leq 40 \mu \text{g/mL} \).

In contrast to gadofullerenes, the tested gadonanotubes caused cytotoxicity at reduced concentrations \( >27 \mu \text{mol/L} \) of Gd(III). Gadofullerenes no exhibited toxicity even at concentrations up to 500 \( \mu \text{mol/L} \) of Gd(III). The difference in toxicity was expected, carbon nanotubes have a fibre-like shape and their toxic properties may be comparable to the observed with other fibrous particles. Also, the toxicity of gadonanotubes varied among different cell lines, some cells lines were more susceptible to gadonanotubes, for example The J774A.1 cell line was highly susceptible to gadonanotubes, in contrast, the NIH/3T3 cell line revealed no toxic effects to the same nanotubes at concentrations up to 100 \( \mu \text{g/mL} \). Regarding the chemistry properties of gadonanotubes, Wang et al reported that at the same concentration (50 \( \mu \text{g/mL} \) naked gadonanotubes were more cytotoxic than gadonanotubes with a shell of PDA-PEG (polydopamine-polyethylene glycol) in the BxPC-3 cell line. This result agrees with previous reports that the functionalization of carbon nanotubes can reduce their toxicity.

Recently, the cytotoxicity of gadonanodiamonds was reported. Rammohan et al demonstrated gadonanodiamonds at concentrations up to 1000 \( \mu \text{g/mL} \) were well tolerated by the MDA-MB-231 cell line. Also, they found the metabolic activity of the SKOV-3, HeLa and NIH/3T3 cell lines was not affected by the exposition to gadonanodiamonds.

Although most studies shown a low grade of toxicity at the tested doses, there is a necessity to understand the interaction between gadolinium-containing carbon nanomaterials and cells for the rational design of contrast agents with biocompatibility and multifunctionality. Considering the discussed studies, it is recommendable the addition of control groups for future research studies (eg for carbon nanomaterials and gadolinium ions). They may help to elucidate the toxicity of each component and the toxicity related to the complex. Also, due to the
production of mono-disperse contrasts with homogeneous gadolinium load is still in its early stages, the robust characterization of the synthesized contrasts may help to establish a proper relationship between the properties of the nanomaterials and their toxicity.

3.2 | In vivo toxicity and biodistribution

In vivo studies are indispensable for determining the efficacy and toxicity of gadolinium-containing carbon nanomaterials. They may help to determine how these new contrast agents are biodistributed, what is the clearance mechanisms, the toxicity related with the materials, the maximum tolerable doses, and the assessment of important parameters that may help to determine whether the contrasts are safety for clinical applicability. Table 1 summary the major biological findings from in vivo studies of gadofullerenes and gadonanotubes.

Until now, most of the revised studies were focused to prove the potential application of the contrast agents and complementary efforts were done to understand their toxicity. As can be appreciated in Table 1, most of the studies reported no acute effects, and just three studies described gadonanotubes and gadofullerenes may promote inflammation and effects at genomic level. However, due to the well-known toxicity of carbon nanomaterials and the toxicity of free gadolinium ions, more studies are needed to clarify the clinical application. For instance, previous works reported carbon nanotubes and fullerenes may promote adverse effects, including inflammation, oxidative stress, DNA damage and mutation, malignant transformation, the formation of granulomas and interstitial fibrosis. Also, owing the toxicity of free gadolinium ions, it is essential to carry out bioavailability studies by their potential dissociation from the carbon nanostructure. It takes significance because even metal impurities can be released from the carbon nanotube structure despite their apparent encapsulation by carbon. Particularly, the concern emerges by the presence of gadolinium in the brain of patients that received repeated administration of chelated gadolinium contrast agents for MRI. The dechelation of free Gd(III) ions from unstable contrast agents is considered the main cause for the observed accumulation. Also, it was reported a relation between the onset of nephrogenic systemic fibrosis (NSF) and the administration of gadolinium contrast agents in patients suffering from severe renal disease. Although the pathogenic mechanism of nephrogenic systemic fibrosis is not fully understood, the presence of free Gd(III) ions is considered as a possible cause. In patients with normal renal function, gadolinium contrasts have a pharmacokinetic half-life on the order of 1-2 hours and are excreted unchanged predominantly through the kidneys. However, for patients with renal failure, the pharmacokinetic half-life increases due to the low elimination rate, and in that way, the risk of enzymatic dechelation can increase and thus the presence of toxic gadolinium ions.

Several studies have tested the stability of the new contrasts, for instance, Sitharaman et al used triethylenetetraminehexaacetic acid (TTHA), a compound with high denticity that fills all the co-ordination sites of Gd(III) ions, thus preventing the formation of an inner sphere and inhibiting any improvement in water relaxivity. When they examined the relaxivity of their gadonanotubes with and without TTHA, there were no differences between the groups, corroborating the absence of free Gd(III) ions. The stability of gadonanotubes has also been tested assessing the presence of free Gd(III) in the supernatant after the proper washing of gadonanotubes, by inductively coupled plasma optical emission spectroscopy (ICP-OES) the supernatants showed no evidence of free ions. Regarding gadofullerenes, Gd(III) ions are encapsulated in the fullerene cage, an extraordinarily stable structure that is extremely unlikely to break and release the toxic ions. Han et al discarded the possible release of free Gd(III) ions in vitro by performing a transmetalation assay, finding gadofullerenes functionalized with the short peptide (ZD2) to be stable under biological conditions (eg human serum). Despite the above results, there is a necessity to study the stability in physiological conditions over long periods of time, most of the previous reports analysed the stability during a short time.

In terms of biodistribution, most of the gadolinium-containing carbon nanomaterials tend to be entrapped by the mononuclear phagocyte system, a network of immune and architectural cells that removes foreign material from the bloodstream. The system encompasses monocytes of the blood, macrophages in connective tissue, lymphoid organs, bone marrow, bone, liver and lung. For instance, Mikawa et al evaluated the biodistribution of the hydroxylated gadofullerenes (Gd@C$_{60}$[OH]$_{60}$) in CDF1 mice. Testing the concentration of gadolinium in different organs by ICP-AES (Inductively coupled plasma atomic emission spectroscopy) they found that after their intravenous injection the gadofullerenes were mainly accumulated in lung, liver and spleen (Figure 12A) and 24 hours later they observed a clearance from lungs, meanwhile the concentration in liver and spleen was constant. In a subsequent study, they identified the same biodistribution pattern for a sample of Gd@C$_{82}$[OH]$_{40}$ of high purity. Then, Bolskar et al reported the Gd@C$_{60}$[COOH]$_{10}$ was mainly accumulated in kidneys and by the presence of gadofullerenes in urine they inferred the gadofullerenes could be eliminated via renal filtration. Chen et al found Gd@C$_{82}$[OH]$_{22}$ was mainly distributed in bone followed by pancreas, spleen, kidney and liver. Also, they reported that 24 hours after intraperitoneal administration 50% of the gadofullerenes were excreted by urine and 35% by faeces. Shultz et al reported the f-Gd$_{2}$N$_{2}$C$_{80}$ was mainly accumulated in liver, lung, brain and spleen after brain infusion administration. Then, after 7 days from initial administration they reported a clearance from liver, lungs and spleen, however, the presence of a residual signal of gadofullerenes was observed in all the organs. Han et al reported the ZD2-Gd$_{3}$N@C$_{80}$ had a significant preferential accumulation in kidneys and bladder, and then, after 1 week most of the gadofullerenes were eliminated via renal clearance. Recently, Li et al analysed the biodistribution of Gd@C$_{82}$[O]$_{10}$[OH]$_{22}$ and Gd@C$_{82}$[O]$_{10}$[OH]$_{16}$ and according with T1 MR images the gadofullerenes were mainly accumulated in liver.

The biodistribution of gadonanotubes has also been reported. Avti et al found synthesized gadonanotubes (average diameter 2.05 nm, length 500 nm to 1.5 mm) using gadolinium nanoparticles
as catalysts were mainly accumulated in lungs, brain, kidney, liver and spleen, and based on the biodistribution profile they suggested the gadonanotubes were cleared by renal filtration and hepatobiliary excretion. Marangon et al. evaluated the biodistribution of functionalized gadonanotubes (diameter of 20-30 nm, average length of ≈400 nm) at 12.5 mg/kg and found a high accumulation in bladder after initial administration, then after 5.3 hours they observed a significant decline from bladder. The rapid clearance suggested most of the gadonanotubes were eliminated through the renal excretion route. Also, they found the gadonanotubes induce neither tissue damage, nor inflammatory response, and they do not promote cellular toxicity. Cisneros et al. reported a high lung uptake of surfactant-wrapped 64Cu@GNTs (average diameter 1.4 nm, length 20 nm to 80 nm) and a high retention of the complex, even after

| Nanomaterial | Animal model | Dose administered | Biological response | Ref. |
|--------------|--------------|-------------------|---------------------|-----|
| Gd@C82(OH)40 | CDF1 mice    | 5 μmol Gd/kg      | Gd@C82(OH)40 found in the reticular-endothelial system | 12 |
| Gd@C82(OH)40 | CDF1 mice    | 5 μmol Gd/kg      | Gd-fullerenols observed in the reticular-endothelial system | 44 |
| Gd@C82(C(COOH)2)10 | Fischer 344 female rats | 35 mg/kg | Reticular-endothelial system with polyhydroxyl fullerene | 45 |
| Gd@C82(OH)22 | Kunming mice (tumour model) | 114 and 228 μg/kg and 10-7 mol/kg | Antineoplastic activity | 75 |
| Gd2N2@C80[(DiPEG5000)-(OH)]2 | Fischer 344 female rats (glioma tumour Model) | 0.0131 mmol/L | No toxic effect | 51 |
| Gd@C82(OH)40 | Sprague-Dawley rats | Human mesenchymal stem cells stained with 1.19 × 10−10 mg per cell | No toxic effect | 30 |
| Gd@C82(OH)22 | C57BL/6 mice (tumour model) | 0.1 or 0.5 mmol/kg | Immune system response | 76 |
| Gd2N2@C80[(DiPEG350)-(OH)x] | Fischer 344 T9 rats with brain tumours | 0.0235 mmol/L | Nanoparticles remained after 7 d | 99 |
| Gd2N2@C80(IL-13 peptide) | Athymic Nu/Un, brain tumour model | 0.2 μL/mL | Preferential accumulation in tumours | 27 |
| 177Lu-DOTA-f-Gd2N2@C80 | Brain tumour model | 1.11 MBq of 177 Lu-DOTA-f-Gd2N2@C80 | Nearly 37.5% of the complex remained intact after 52 d | 89 |
| Gd@C82(OH)22 | BALB/c mice | 2 μmol/kg (once a day for 6 times) | Inflammatory response | 81 |
| MWNT/GdL | BALB/c mice | 50 μL of 0.05 mmol/L GdL | 100% survival of animals after over 1 mo | 100 |
| Gd-SWCNTs | Wistar rats | 0.5 mg/kg | No inflammation or organ damage, but a differential effect at the genomic level | 82 |
| Gd-CNTs | C57/Bl6 mice | 5.75 μmol/kg | Signal enhancement in the liver and spleen, and to a much greater extent in the bladder | 72 |
| Gd@GNTs | Normal, tumour-free athymic nude mice | 7.4-11.1 MBq of surfactant-wrapped 64Cu@GNTs | Greater accumulation in the lungs | 60 |
| IL-13-Gd2N2@C80(NH2)2x | Brain tumour model | ~250 μL (~0.25 mmol) | Preferential accumulation in tumours | 23 |
| Gd2N2@C80[(DiPEG350)-(OH)x] | BALB/c mice | 48 μmol/kg | Nanoparticles accumulated in the reticular-endothelial system | 90 |
| NDs-Gd | SCID-beige mice | Cells labelled with NDG at a concentration of 500 μmol/L Gd(Ill) | Preferential accumulation in tumours | 29 |
| ZD2-Gd2N2@C80 | Tumour model | 1.7 μmol/kg | Dense accumulation in tumours | 25 |
| MWCNT-Gd@PDA-PEG | Male nude mice | 50 mL of 3 mg/mL | Preferential accumulation in tumours and in regional lymph nodes | 65 |
| PEG-GMF-PPy NP | Tumour model | 100 μL (Gd concentration: 50 ppm) of PEG-GMF-PPy | Preferential accumulation in tumours and no noticeable organ damage | 101 |
48 hours. Whang et al. investigated the biodistribution of GdN@CQDs-MWCNTs (mean diameter of 30 nm with length of about 100-300 nm) and reported a high accumulation in liver 4 hours after intravenous injection. They analysed the potential adverse side effects by evaluating the body weight of mice, which was found to be stable.

As can be appreciated, most of the gadolinium-containing carbon nanomaterials tend to be entrapped by filtration organs (e.g., liver, lungs, bladder, spleen, and kidneys). The pattern agrees with those reported for fullerenes and carbon nanotubes. For example, it was reported that long carbon nanotubes are mainly accumulated in lungs,91 Avti et al. observed the same pattern for carbon nanotubes of 500 nm to 1.5 mm of length, by contrast. Also, it is well-known small carbon nanotubes can be accumulated in bladder and kidneys,91 Marangon et al. observed the functionalized carbon nanotubes with an average length of ≈400 nm, were mainly accumulated in bladder and kidneys.

Until now, most of the reviewed works reported elimination percentages of gadonanotubes and gadofullerenes, but not the complete elimination from organs. This long-term accumulation may represent a risk. A number of reports have found pristine CNTs remain in lungs for months or even years after pulmonary deposition, even more, the accumulation is associated with chronic inflammation and tissue damage.44,92 Particularly, the accumulation of MWCNTs in lungs is associated with fibrotic-like lesions via non-resolved chronic inflammation83 and the chronic exposure to SWCNTs may cause malignant transformation of human lung epithelial cells and induced tumorigenesis in mice.52 The hepatic accumulation of carbon nanotubes is associated with the induction of a local immune response and liver damage.93 The accumulation in kidney may induce toxicity due increased oxidative stress, mitochondrial damage or DNA damage.94,95 In spleen, the accumulation of carbon nanotubes has been associated with immunotoxicity.96

As can be appreciated, carbon nanotubes and fullerenes are associated with toxic effects, however, a number of reports have found the functionalization with functional groups, polymers and biomolecules may modulate the biodistribution and elimination.32,91 Carboxylic acid-functionalized fullerenes have exhibited high levels of retention (even 72 hours after intravenous administration) in contrast hydroxyl-functionalized fullerenes are rapidly excreted in urine.97 The functionalization also improves the dispersion of carbon nanomaterials, Marangon et al.72 found well-dispersed carbon nanotubes prevent lung accumulation and can be eliminated in urine. It is also important to remark the preferred accumulation in a desired tissue can be modulated by the functionalization of the carbon structure with antibodies, peptides or polysaccharides. Fillmore et al.,27 Zheng et al.55 and Han et al.25 reported the active targeting of implanted tumours in mice functionalizing gadofullerenes with peptides with high affinity by overexpressed membrane proteins on tumour cells or extracellular matrix components.

As shown, new formulations of gadolinium-containing carbon nanomaterials are being evaluated in laboratory models. However, more in vitro and in vivo studies are essential to ensure the new contrast agents are useful for MR imaging. Much remains unknown, it is recommended future research evaluate the chronic toxicity over long periods of time and the acute toxicity administrating high doses, the transport mechanisms, fate and adverse health effects due gadolinium-containing carbon nanomaterials.
A critical evaluation was conducted of the advantages of gadolinium-containing carbon nanomaterials over conventional chelated gadolinium contrast agents. Their enhanced relaxivity allows for reliable imaging of cellular and molecular biomarkers with a lower dose of Gd(III), thus reducing the risk of toxicity from free Gd(III) ions. The physical and chemical properties of carbon nanomaterials have enabled the fabrication of contrast agents with multifunctionality as well as with active targeting capability, which encompasses multimodal imaging and the combination of imaging with therapy with high specificity. Nowadays, there are intense efforts to design new T1 MRI nanoprobes based on gadolinium-containing carbon nanomaterials. However, several issues should be overcome, the production of mono-disperse nanomaterials with controlled size and a homogeneous gadolinium load is still in its early stages, and require better and standardized synthesis methods. The new contrast must be tested with standard characterization techniques and valid methods to establish the proper relationship between the characteristics of the nanomaterial and its probable toxicity in order to understand its behaviour in living systems. Also, more preclinical studies as biodistribution, biocompatibility, pharmacokinetics and long-term stability are needed to clarify the potential clinical use of these nanomaterials.

ACKNOWLEDGEMENTS
This work was supported by the National Autonomous University of Mexico (UNAM; Grant DGAPA-IN104919).

CONFLICT OF INTEREST
No conflict of interest exits in the submission of this manuscript.

AUTHOR CONTRIBUTION
ARG performed the literature research and drafted the manuscript; MR, PGL, LAM and VAB revised the manuscript, drafted the manuscript, edited the final version and gave the final approval for the article to be published.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article.

ORCID
Andrés Rodríguez-Galván https://orcid.org/0000-0001-7208-773X
Vladimir A. Basiuk https://orcid.org/0000-0001-7864-9203

REFERENCES
1. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15:e395-e403.
2. Tempany CMC, Jayender J, Kapur T, et al. Multimodal imaging for improved diagnosis and treatment of cancers. Cancer. 2015;121:817-827.
3. Constantine G, Shan K, Flamm SD, Sivananthan MU. Role of MRI in clinical cardiology. Lancet. 2004;363:2162-2171.
4. Nitz WR, Reimer P. Contrast mechanisms in MR imaging. Eur Radiol. 1999;9:1032-1046.
5. Trattnig S, Pinker K, Ba-Ssalamah A, Nöbauer-Huhmann I-M. The optimal use of contrast agents at high field MRI. Eur Radiol. 2006;16:1280-1287.
6. U.S. Food and Drug Administration. Developing medical imaging drug and biological products part 1: Conducting safety assessments; 2019.
7. Ni D, Bu W, Ehrlebing EB, Cai W, Shi J. Engineering of inorganic nanoparticles as magnetic resonance imaging contrast agents. Chem Soc Rev. 2017;46:7438-7468.
8. Helm L. Optimization of gadolinium-based MRI contrast agents for high magnetic-field applications. Future Med Chem. 2010;2:385-396.
9. Peng Y-K, Tsang SCE, Chou P-T. Chemical design of nanoprobes for T1-weighted magnetic resonance imaging. Mater Today. 2016;19:336-348.
10. Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology. 2015;275:630-634.
11. Ananta JS, Godin B, Sethi R, et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol. 2010;5:815-821.
12. Mikawa M, Kato H, Okamura M, et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjugate Chem. 2001;12:510-514.
13. Sitharaman B, Kissell KR, Hartman KB, et al. Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun. 2005;915-917.
14. Sitharaman B, Wilson LJ. Gadonanotubes as new high-performance MRI contrast agents. Int J Nanomed. 2006;1:291-295.
15. Sethi R, Mackeyev Y, Wilson LJ. The Gadonanotubes revisited: a new frontier in MRI contrast agent design. Inorg Chim Acta. 2012;393:165-172.
16. Kuznik N, Tomczyk MM. Multiwalled carbon nanotube hybrids as MRI contrast agents. Beilstein J Nanotechnol. 2016;7:1086-1103.
17. Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine. 2008;3:201-213.
18. Zheng J-P, Zhen M-M, Wang C-R, Shu C-Y. Recent progress of molecular imaging probes based on gadofullerenes. Chinese J Anal Chem Chinese. 2012;40:1607-1615.
19. Popov AA, Yang S, Dunsch L. Endohedral fullerene modification enhances T1 contrast. Radiology. 2010;260:650-659.
20. Ghiasi KB, Olmstead MM, Balch AL. Gadolinium-containing endohedral fullerenes: structures and function as magnetic resonance imaging (MRI) agents. Dalton Trans. 2014;43:7346-7358.
21. Li T, Dorn HC. Biomedical applications of metal-encapsulated fullerene nanoparticles. Small. 2017;13:1603152.
22. Sitharaman B, Wilson LJ. Gadofullerenes and gadonanotubes: a new paradigm for high-performance magnetic resonance imaging contrast agent probes. J Biomed Nanotechnol. 2007;3:342-352.
23. Li T, Murphy S, Kiselev B, et al. A new interleukin-13 amino-coated gadolinium metallofullerene nanoparticle for targeted MRI detection of glioblastoma tumor cells. J Am Chem Soc. 2015;137:7881-7888.
27. Fillmore HL, Shultz MD, Henderson SC, et al. Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors. *Nanomedicine*. 2011;4:449-458.
28. Na HB, Hyeon T. Nanostructured T1 MRI contrast agents. *J Mater Chem*. 2009;19:6267-6273.
29. Ramamon J, MacRenaris KW, Moore TK, et al. Nanodiamond-gadolinium(III) aggregates for tracking cancer growth in vivo at high field. *Nano Lett*. 2016;16:7551-7564.
30. Anderson SA, Lee KK, Frank JA. Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. *Invest Radiol*. 2006;41:332-338.
31. Zhang M, Liu X, Huang J, et al. Ultrasmall graphene oxide based T1 MRI contrast agent for in vitro and in vivo labeling of human mesenchymal stem cells. *Nanomedicine*. NBM. 2018;14:2475-2483.
32. Hong G, Diao S, Antaris AL, Dai H. Carbon nanomaterials for biological imaging and nanomedicinal therapy. *Chem Rev*. 2015;115:10816-10906.
33. Rodríguez-Galván A, Amelien-Sarria O, Rivera M, del Carrero-Castro MP, Basiuk VA. Adsorption and self-assembly of anticancer antibiotic doxorubicin on single-walled carbon nanotubes. *NANO*. 2015;11:1650038.
34. Rodríguez-Galván A, Heredia A, Amelien-Sarria O, Rivera M, Medina L, Basiuk VA. Non-covalent attachment of silver nanoclusters onto single-walled carbon nanotubes with human serum albumin as linking molecule. *Appl Surf Sci*. 2015;331:271-277.
35. Zhang Z, Nair SA, McMurry TJ. Gadolinium meets medicinal chemistry: MRI contrast agent development. *Curr Med Chem*. 2005;12:751-778.
36. Zhang S, Sun D, Li X, Pei F, Liu S. Synthesis and solvent enhanced relaxation property of water-soluble endohedral metallofullerenols. *Fullerenes Sci Technol*. 1997;5:1635-1643.
37. Manus LM, Mastarone DJ, Waters EA, et al. Gd(III)-nanodiamond conjugates for MRI contrast enhancement. *Nano Lett*. 2010;10:484-489.
38. Shen A-J, Li D-L, Cai X-J, et al. Multifunctional nanocomposite based on graphene oxide for in vitro hepatocarcinoma diagnosis and treatment. *J Biomed Mater Res, Part A*. 2012;100A:2499-2506.
39. Tóth É, Helm L, Merbach A. Relativity of gadolinium(III) complexes: theory and mechanism. In: Merbach A, Helm L, Tóth É, eds. *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging*. United Kingdom: John Wiley & Sons, Ltd; 2013:25-81.
40. Ma Q, Jobb M, Tweedle MF, Wilson LJ. The gadonanotubes: structural origin of their high-performance MRI contrast agent behavior. *J Mater Chem B*. 2013;1:5791-5797.
41. Kato H, Suenaga K, Mikawa M, et al. Syntheses and EELS characterization of water-soluble multi-hydroxy Gd@C_{60} fullerolens. *Chem Phys Lett*. 2000;324:255-259.
42. Nishihori E, Iwata K, Sakata M, et al. Anomalous endohedral structure of Gd@C_{60} metallofullerenes. *Phys Rev B*. 2004;69:113412.
43. Bottrill M, Kwok L, Long NJ. Lanthanides in magnetic resonance imaging. *Chem Soc Rev*. 2006;35:557-571.
44. Okumura M, Mikawa M, Yokawa T, Kanazawa Y, Kato H, Shinohara H. Evaluation of water-soluble metallofullerenes as MRI contrast agents. *Acad Radiol*. 2002;9:S495-S497.
45. Bolksar RD, Benedetto AF, Husebo LO, et al. First soluble M@C_{60} derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C_{60}[C(OOH)]_{10} as a MRI contrast agent. *J Am Chem Soc*. 2002;125:5471-5478.
46. Laus S, Sítharaman B, Tóth É, et al. Destroying gadofullerene aggregates by salt addition in aqueous solution of Gd[C_{60}(OH)]_{10} and Gd[C_{60}[C(OOH)]_{10}. *J Am Chem Soc*. 2005;127:9368-9369.
47. Tóth É, Bolksar RD, Borel A, et al. Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. *J Am Chem Soc*. 2005;127:799-805.
48. Moghaddam SE, Shayaneganfar F, Bryant RG, Wilson LJ. The gadonanotubes as high-performance MRI contrast agents: the unappreciated role of the carbon nanotube component at low magnetic fields. *Ecs J Solid State Sci*. 2017;6:S3173-M3180.
49. Sítharaman B, Bolskar RD, Rusakova I, Wilson LJ. Gd@C_{60}[C(OOH)]_{10} and Gd[C_{60}(OH)]_{10}: nanoscale aggregation studies of two metallofullerenes MRI contrast agents in aqueous solution. *Nano Lett*. 2004;4:2373-2378.
50. Laus S, Sítharaman B, Tóth É, et al. Understanding paramagnetic relaxation phenomena for water-soluble gadofullerenes. *J Phys Chem B*. 2007;111:5633-5639.
51. Fatouros PP, Corwin FD, Chen Z-J, et al. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. *Radiology*. 2006;240:756-764.
52. Enoch S, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. *J Magn Reason Imaging*. 1999;9:228-232.
53. Allen MJ, MacRenaris KW, Venkata subramanian PN, Meade TJ. Cellular delivery of MRI contrast agents. *Chem Biol*. 2004;11:301-307.
54. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. *Nat Comm*. 2018;9:1410.
55. Zheng J, Liu Q, Chen Z, et al. Multifunctional imaging probe based on gadofulleride nanoplatform. *Nanoscale*. 2012;4:3669-3672.
56. Gu M-J, Li K-F, Zhang L-X, et al. In vitro study of novel gadolinium-loaded liposomes guided by GBI-10 aptamer for promising tumor targeting and tumor diagnosis by magnetic resonance imaging. *Int J Nanomed*. 2015;10:5187-5204.
57. Zhang L-X, Li K-F, Wang H, et al. Preparation and in vitro evaluation of a MRI contrast agent based on aptamer-modified gadolinium-loaded liposomes for tumor targeting. *AAPS PharmSciTech*. 2017;18:1564-1571.
58. Rodríguez-Galván A, Contreras-Torres FF, Basiuk EV, Alvarez-Zauco E, Heredia A, Basiuk VA. Aggregation of human serum albumin on graphite and single-walled carbon nanotubes as studied by scanning probe microscopies. *J Nanosci Nanotechno*. 2011;11:5491-5498.
59. Rodríguez-Galván A, Contreras-Torres FF, Basiuk EV, Heredia A, Basiuk VA. Deposition of silver nanoparticles onto human serum albumin-functionalised multi-walled carbon nanotubes. *Can J Chem Eng*. 2013;91:264-270.
60. Cisneros BT, Law JJ, Matson ML, Azhdarinia A, Sevick-Muraca EM, Wilson LJ. Stable confinement of positron emission tomography and magnetic resonance agents within carbon nanotubes for biomedical imaging. *Nanomedicine*. 2014;9:2499-2509.
61. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. *Nanotechnol*. 2007;2:47-52.
62. Luo J, Wilson JD, Zhang J, et al. A dual PET/MR imaging probe: {^{124}I} labeled Gd@C_{60}, *Appl Sci-Basel*. 2012;2:465-478.
63. Matson ML, Villa CH, Ananta JS, Law JJ, Scheinberg DA, Wilson LJ. Encapsulation of α-particle-emitting {^{225}Ac}{^{217}At} ions within carbon nanotubes. *J Nucl Med*. 2015;56:897-900.
64. Peci T, Dennis TJS, Baxendale M. Iron-filled multiwalled carbon nanotubes surface-functionalized with paramagnetic Gd(III): a candidate dual-functioning MRI contrast agent and magnetic hyperthermia structure. *Carbon*. 2015;87:226-232.
65. Wang S, Lin Q, Chen J, Gao H, Fu D, Shen S. Biocompatible polydopamine-encapsulated gadolinium-loaded carbon nanotubes for MRI and color mapping guided photothermal dissection of tumor metastasis. *Carbon*. 2017;112:53-62.
66. Zhang M, Wang W, Wu F, Yuan P, Chi C, Zhou N. Magnetic and fluorescent carbon nanotubes for dual modal imaging and...
photothermal and chemo-therapy of cancer cells in living mice. Carbon. 2017;123:70–83.
67. Srivastava AK, Kadayakkara DK, Bar-Shir A, Gilad AA, McMahon MT, Bulte JWM. Advances in using MRI probes and sensors for in vivo cell tracking as applied to regenerative medicine. Dis Model Mech. 2015;8:323-336.
68. Sitharaman B, Tran LA, Pham QP, et al. Gadofullerenes as nanoscale magnetic labels for cellular MRI. Contrast Media Mol. 2007;2(3):139-146.
69. Hassan AA, Chan BT-Y, Tran LA, et al. Serine-derivatized gadonanotubes as magnetic nanoprobes for intracellular labeling. Contrast Media Mol. 2010;5(5):34-38.
70. Holt BD, Law JJ, Boyer PD, Wilson LJ, Dahl KN, Islam MF. Subcellular partitioning and analysis of Gd3+-loaded ultrashort single-walled carbon nanotubes. ACS Appl Mater Interfaces. 2015;7:14593-14602.
71. Avti PK, Caparelli ED, Sitharaman B. Cytotoxicity, cytocompatibility, cell-labeling efficiency, and in vitro cellular magnetic resonance imaging of gadolinium-catalyzed single-walled carbon nanotubes. J Biomed Mater Res A. 2013;101:3580-3591.
72. Marangoń I, Ménard-Moyon C, Kolosnjaj-Tabi J, et al. Covalent functionalization of multi-walled carbon nanotubes with a gadolinium chelate for efficient T1-weighted magnetic resonance imaging. Adv Funct Mater. 2014;24:7173-7186.
73. Tran LA, Krishnamurthy R, Muthupillai R, et al. Gadonanotubes as magnetic nanolabels for stem cell detection. Biomaterials. 2010;31:9482-9491.
74. Gizzatov A, Hernández-Rivera M, Keshishian V, et al. Surfactant-free Gd3+-ion-containing carbon nanotube MRI contrast agents for stem cell labeling. Nanoscale. 2015;7:12085-12091.
75. Chen C, Xing G, Wang J, et al. Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett. 2005;5:2050-2057.
76. Liu Y, Jiao F, Qiu Y, et al. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-α mediated cellular immunity. Biomaterials. 2009;30:3934-3945.
77. Tang AM, Ananta JS, Zhao H, et al. Cellular uptake and imaging studies of gadolinium-loaded single-walled carbon nanotubes as MRI contrast agents. Contrast Media Mol. 2011;6(2):93-99.
78. Servant A, Jacobs I, Bussy C, et al. Gadolinium-functionalised multi-walled carbon nanotubes as a T1 contrast agent for MRI cell labelling and tracking. Carbon. 2016;97:126-133.
79. Liu Y, Zhao Y, Sun B, Chen C. Understanding the toxicity of carbon nanotubes. Acc Chem Res. 2013;46:702-713.
80. Dumortier H, Lacotte S, Pastorin G, et al. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett. 2006;6:1522-1528.
81. Chen Z, Liu Y, Sun B, et al. Polyhydroxylated metallofullerenols stimulate IL-1β secretion of macrophage through TLRs/MyD88/NF-κB pathway and NLRP3 inflammasome activation. Small. 2014;10:2362-2372.
82. Avti PK, Talukdar Y, Sirotkin MV, Shroyer KR, Sitharaman B. Toward single-walled carbon nanotube–gadolinium complex as advanced MRI contrast agents: pharmacodynamics and global genomic response in small animals. J Biomed Mater Res B. 2013;101B:1039-1049.
83. Boyles MSP, Stoehr LC, Schlinkert P, Himly M, Duschl A. The significance and insignificance of carbon nanotube-induced inflammation. Fibers. 2014;2:45-74.
84. Goodarzi S, Da Ros T, Conde J, Sefat F, Mozafari M. Fullerene-based biomaterials. Adv. Mater. 2017;19:2790-2796.
85. Guo BJ, Yang ZL, Zhang LJ. Gadolinium deposition in brain: current scientific evidence and future perspectives. Front Mol Neurosci. 2018;11:335.
86. Choi JW, Moon W-J. Gadolinium deposition in the brain: current updates. Korean J Radiol. 2019;20:134-147.
87. Goodarzi S, Moller P, Clausen PA, et al. Biodistribution of carbon nanotubes in animal models. Basic Clin Pharmacol. 2017;121:30-43.
88. Wang L, Luqiptong S, Castranova V, et al. Carbon nanotubes induce malignant transformation and tumorigenesis of human lung epithelial cells. Nano Lett. 2011;11:2796-2803.
89. Principi E, Girardello R, Bruno A, et al. Systemic distribution of single-walled carbon nanotubes in a novel model: alteration of biochemical parameters, metabolic functions, liver accumulation, and inflammation in vivo. Int J Nanomed. 2016;11:4299-4316.
90. Cui D, Tian F, Ozkan CS, Wang M, Gao H. Effect of single wall carbon nanotubes on human HEK293 cells. Toxicol Lett. 2005;155:73-85.
91. Tang S, Tang Y, Zhong L, et al. Short- and long-term toxicities of multi-walled carbon nanotubes in vivo and in vitro. J Appl Toxicol. 2012:32:900-912.
92. Deng X, Wu F, Liu Z, et al. The splenic toxicity of water soluble multi-walled carbon nanotubes in mice. Carbon. 2009;47:1421-1428.
93. Singh R, Pantaratoto D, Lacerda L, et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci USA. 2006;103:3357-3362.
94. Shu C, Corwin FD, Zhang J, et al. Facile preparation of a new gadofullerenes-based magnetic resonance imaging contrast agent with high 1H relaxivity. Bioconjugate Chem. 2009;20:1186-1193.
95. Zhang J, Fatouros PP, Shu C, et al. High relaxivity trivalent nitride (Gd,N) metallofullerene MRI contrast agents with optimized functionality. Bioconjugate Chem. 2010;21:610-615.
96. Richard C, Doan B-T, Beloeil J-C, Bessodes M, Toth E, Scherman D. Noncovalent functionalization of carbon nanotubes with amphiphilic Gd3+ chelates: toward powerful T1 and T2 MRI contrast agents. Nano Lett. 2008;8:232-236.
97. Wang S, Zhou Z, Yu G, et al. Gadolinium metallofullerene-polypyrrole nanoparticles for activatable dual-modal imaging-guided photothermal therapy. ACS Appl Mater Inter. 2018;10:28382-28389.